CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Daunorubicin (liposomal) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002093
NCT00002093Phase 3Completed
CompareCT.gov

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

Nexstar Pharmaceuticals·interventional·Posted Aug 31, 2001·Updated Jun 24, 2005

In Brief

A Phase 3 clinical trial evaluating Daunorubicin (liposomal), Bleomycin sulfate, and 2 other interventions for Sarcoma, Kaposi and HIV Infections. Completed, across 13 sites.

Detailed Summary

To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered in combination with antiretroviral therapy. To compare the duration of responses, response rates, and times to response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Kaposi, HIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Daunorubicin (liposomal)drug

Bleomycin sulfatedrug

Vincristine sulfatedrug

Doxorubicin hydrochloridedrug